About Myasthenia Gravis Foundation of America
The Myasthenia Gravis Foundation of America concentrates its funding on translational and clinical research that advances understanding, diagnosis, and treatment of myasthenia gravis (MG). Grants are targeted to university labs and clinical research centers pursuing antibody-specific mechanisms (MuSK and AChR), biomarker development, and patient-centered outcome measures, with some investment in programmatic networks and health-services research to accelerate clinical application.
Focus Areas
Mechanistic and antibody-specific research into MuSK autoantibodiesBiomarker discovery and validation for AChR- and MuSK-positive MGPreclinical models and translational studies to predict therapeutic outcomes (CAART and similar approaches)Multiomics immunological profiling to identify MG biomarkersPatient-reported outcome development and research into ocular myasthenia careClinical network pilot studies (MG Net) and capacity-building for multicenter MG research
Who They Fund
patients with myasthenia gravis
About Myasthenia Gravis Foundation of America
Myasthenia Gravis Foundation of America Inc. centers its giving on translational and clinical research for myasthenia gravis, with recent awards aimed at antibody-specific mechanisms, biomarker validation, and patient-centered outcomes. One of the largest recent grants went to Yale University for work on defining new autoimmune mechanisms in seronegative MG, while another Yale award supported mechanistic study of the MuSK-specific autoantibody repertoire. The foundation’s portfolio also reaches beyond lab science into clinical research infrastructure and outcome measurement, including support for MG Net pilot studies at The George Washington University and a patient-reported outcome measure project at the University of Michigan. Its grants are sized for research projects rather than broad operating support, with awards often used to test hypotheses, validate diagnostic tools, or build multicenter research capacity. Recent grantees also include institutions working on AChR autoantibody effector functions, multiomics biomarker work, and studies tied to MG-related health disparities. The overall pattern is a focused research program built around improving understanding, diagnosis, and treatment of MG through academic and clinical research settings.
What Myasthenia Gravis Foundation of America Funds
A major theme in the portfolio is mechanistic MG research. Yale University received $225,000 for measuring AChR autoantibody effector functions, and later $110,000 for novel mechanistic insights into the MuSK-specific autoantibody repertoire. Biomarker work is another clear emphasis: Uppsala University was awarded $110,000 to validate diagnostic and prognostic serum biomarkers for AChR antibody seropositive MG, while Duke University School of Medicine received $110,000 for multiomics-based immunological biomarker analysis. The foundation also funds patient-centered and clinical research. University of Michigan received $55,000 to validate a patient-reported outcome measure for ocular myasthenia gravis. In addition, Alira Health received three separate $10,000 awards in 2025 for studies on race and ethnicity in MG, race and income in MG care, and physical activity participation among patients with myasthenia.
How Myasthenia Gravis Foundation of America Gives
Typical awards cluster around research-project scale funding: the median grant size is $110,000, with the 25th percentile at $50,000 and the 75th percentile at $159,999. The recent record shows repeat support for some recipients and programs, including The George Washington University’s MG Net pilot studies program in both 2023 and 2025. The foundation gives through named grant programs, including research grants, pilot project awards, post-doctoral fellowship support, and a clinician-scientist development award. Both unsolicited and program-based grant paths appear in the active programs listed.
Financial Snapshot
Annual Giving
$520K
Total Assets
$15.3M
Total Revenue
$7.6M
Total Expenses
$7.1M
Typical Grant Size
Most grants fall between $50K and $160K, with a median of $110K.
25th Percentile
$50K
Median
$110K
75th Percentile
$160K
Geographic Reach
National10 states funded
About 20% of grants go to recipients in CT.
Funding intensity
LowHigh
Headquarters
Leadership
Justin Stachtiaris
Funding intensity
LowHigh
Where Myasthenia Gravis Foundation of America Funds
Top 2 recipient countries by grant volume for Myasthenia Gravis Foundation of America.
| Rank | Country | Grants | Total | Share |
|---|---|---|---|---|
| 1 | United StatesDomestic | 19 | $2.3M | 95.0% |
| 2 | Sweden |
Unlock Deep Analysis
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeSee Similar Funders
Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeExplore related grant guides
Want a Personalized Pitch for Myasthenia Gravis Foundation of America?
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Free plan available
No contracts
Cancel anytime